RxDoctor Payments DataLook up a doctor →

Abhishek Srivastava, MD

Urology · Myrtle Beach, SCNPI 1083980064

Payments from drug & device makers

$121,052in general payments, 2019–2025

Across 348 payments — averaging $347.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$87K
  • Intuitive Surgical$18K
  • Johnson & Johnson$4K
  • Sumitomo Pharma America, Inc.$2K
  • Procept Biorobotics Corporation$2K
  • Neotract Inc.$1K
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$6,09015%
  • Speaking & faculty fees$7,00017%
  • Travel & lodging$6,73116%
  • Food & beverage$8,78821%
  • Education$12,83431%
  • Gifts$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,052 in reported general payments places this provider in the 95th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,395,004
Medicare patients
1,298
Services billed
30,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron48$64,138
MyrbetriqMirabegron17$19,627
Tamsulosin Hcl293$4,329
Testosterone15$3,472
Estradiol30$2,346
Solifenacin Succinate51$1,854
Potassium Citrate ErPotassium Citrate13$1,519
Tadalafil23$1,474
Testosterone Cypionate30$1,198
Finasteride58$855
Oxybutynin Chloride ErOxybutynin Chloride33$616
NitrofurantoinNitrofurantoin Macrocrystal13$577
Ketorolac Tromethamine14$216
Oxybutynin Chloride16$205
Levofloxacin74$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$2,488$64,13848 claims
Astellas Pharma US IncMyrbetriq$335$19,62717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 196 urology providers in South Carolina.

Other urology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →